Showing results (281-290 of 520) with videos related to

Sort By:
Pageof 52
Pediatrics|August 3, 2001
Effect of the Vaccines for Children program on physician referral of children to public vaccine clinics: a pre-post comparisonR K Zimmerman, T A Mieczkowski, H M Mainzer, et al.
Journal of Community Health|August 12, 2019
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 YearsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Cancer|December 15, 1995
A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adultsP T Ho, K Zimmerman, L H Wexler, et al.
Human Vaccines & Immunotherapeutics|January 12, 2019
An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysisAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Journal for Healthcare Quality : Official Publication of the National Association for Healthcare Quality|April 7, 2010
Establish the habit: influenza vaccination for health care personnelMary Patricia Nowalk, Chyongchiou J Lin, Richard K Zimmerman, et al.
Vaccine|July 13, 2010
Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenzaBruce Y Lee, Rachel R Bailey, Ann E Wiringa, et al.
Vaccine|March 9, 2019
Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general populationAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Development (Cambridge, England)|December 19, 2003
DAF-5 is a Ski oncoprotein homolog that functions in a neuronal TGF beta pathway to regulate C. elegans dauer developmentLi S da Graca, Karen K Zimmerman, Melissa C Mitchell, et al.
Vaccine|June 14, 2017
Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling studyJay V DePasse, Mary Patricia Nowalk, Kenneth J Smith, et al.
Vaccine|November 6, 2022
Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-oldAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Pageof 52